Clinical Trial Update: Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial assessing aprotinin's impact on transfusion needs in elective spinal fusion; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blood Loss Associated with Surgery
• Postoperative Hemorrhage
• Spinal Fusion Surgery Complications

Drugs mentioned

• Aprotinin (aprotinin)

Snippet

Sponsor: Bayer | Conditions: Blood Loss, Surgical, Postoperative Hemorrhage | Phase 3 | Status: TERMINATED